// App-Quantinova.ai

4078 : Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis.

Researchers

Presenter

  • Michael Teufel

Principal Investigators

  • Karl Kochert

  • Gerold Meinhardt

  • Jordi Bruix

Medical Centers

  • Bayer HealthCare Pharmaceuticals, Whippany, NJ

  • Bayer, Berlin, Germany

  • BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain

Locations

  • United States

  • Germany

  • Spain

Companies

  • Bayer HealthCare Pha

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Alpha-fetoprotein

  • Regenerating islet-derived 1 alpha

  • Hepatocyte growth factor receptor

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Alfa-fetoprotein

  • Regorafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01774344

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved